YBGJ · Yubo International Biotech Ltd · Fails to Deliver

Substantial doubt about the company's ability to continue as a going concern.

“The accompanying interim unaudited consolidated financial statements for the three and six months ended June 30, 2026 and 2025 included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. To date, we have not yet established an ongoing source of revenues and cash flows sufficient to cover our operating costs and allow us to continue as a going concern. For the three and six months ended June 30, 2026, we had net losses of $268,721 and $563,747, respectively. These factors, among others, raise substantial doubt about our ability to continue as a going concern for a reasonable period of time. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern.”